[Federal Register Volume 71, Number 54 (Tuesday, March 21, 2006)]
[Notices]
[Pages 14223-14224]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-2735]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections

[[Page 14224]]

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract 
proposals and the discussions could disclose confidential trade secrets 
or commercial property such as patentable material, and personal 
information concerning individuals associated with the contract 
proposals, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, SBIR Topic 221 Oral Bioavailability Enhancement of Drug 
Candidates Using Innovative Excipients.
    Date: March 23, 2006.
    Time: 12 p.m. to 5 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, 6130 Executive Blvd., 
Rockville, MD 20852. (Telephone Conference Call).
    Contact Person: Lalita D. Palekar, PhD, Scientific Review 
Administrator, Special Review and Resources Branch, Division of 
Extramural Activities, National Cancer Institute, National 
Institutes of Health, 6116 Executive Boulevard, Room 8105, Bethesda, 
MD 20892-7405. (301) 496-7575.
    This notice is being published less than 15 days prior to the 
meeting date due to administrative concerns regarding a non-
responsive proposal.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: March 13, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-2735 Filed 3-20-06; 8:45 am]
BILLING CODE 4140-01-M